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| INTRODUC TI ON
Migraine is a highly prevalent neurological disorder that is associated with substantial clinical and socioeconomic impact. 1 Calcitonin gene-related peptide (CGRP) is a neuropeptide, with two major forms (α and β), that is widely distributed in nociceptive pathways in the central and peripheral nervous systems and plays a key role in the signaling pathways involved in the pathophysiology of migraine. [2] [3] [4] Thus, CGRP and one of the CGRP receptors in the calcitonin family have been targets of therapeutic interventions for the prevention of migraine. 4, 5 Population pharmacokinetic (PK) analyses guide drug development and inform recommendations on individualized treatment (eg, dose adjustments) by assessing the variability in PK of a drug in individuals of a population, as well as variability based on various characteristics of individuals. 6, 7 Dose-response and exposure-response analyses further the understanding of drug effects by evaluating which dose and exposure levels are associated with efficacious benefit with the least risk of adverse effects. 6 Considering that migraine is a heterogeneous disorder, 8, 9 it is valuable to assess whether a migraine-targeted therapy exhibits variability across individuals to appropriately individualize treatment for optimal outcomes. Eptinezumab (ALD403) is a humanized anti-CGRP antibody with an IgG1 backbone that binds to both the α and β forms of CGRP and is currently under development for migraine prevention. In controlled clinical studies, it has demonstrated efficacy compared to placebo in the prevention of migraine in patients with episodic migraine (EM) and chronic migraine (CM). [10] [11] [12] [13] [14] This report describes a population PK modeling analysis conducted for the IV administration of eptinezumab at single doses of 10-1000 mg in healthy subjects and in patients with EM and CM from eight studies in the eptinezumab clinical program. [11] [12] [13] A further goal was to assess the dose-and exposure-response relationships of selected endpoints in patients with EM and CM who received eptinezumab.
| MATERIAL S AND ME THODS

| Study population
The eight studies with available PK and pharmacodynamic (PD) data are listed in Table 1 . All eight studies were included in the population PK analysis and included a total of 2123 patients and healthy volunteers who received eptinezumab. The PK dataset included only PK information related to IV administration of eptinezumab over approximately 30 minutes to 1 hour at dose levels of 10-1000 mg in healthy subjects and in patients with EM and CM. The concentrations of free eptinezumab were measured in plasma from all eptinezumab-treated patients using validated methods. Three clinical studies (CLIN-005, CLIN-006, and CLIN-011), involving 2543 patients who received eptinezumab at doses ranging from 10 to 300 mg or placebo, provided efficacy data for the exposure-response analysis. This exposure-response analysis population is larger than the PK population because it included patients who received placebo.
| Population pharmacokinetics
| Model
The current population PK analysis was based on the recommendations provided in key guidance documents from the US Food and Drug Administration (FDA) and European Medicines Agency (EMA). 6, 7 The population PK modeling process used a nonlinear mixed-effects approach as described in Section 3b of the FDA guidance. 7 The population PK analysis was performed using Phoenix although other models were also investigated (one-and three-compartment models). The models had the following form:
TA B L E 1 Pharmacokinetic and exposure-response analyses population
where Cij is the concentration level at the j th collection time t j for subject i; m represents the set of equations that define the model; Di represents dosing history for subject i; Φi is the vector of p PK parameters for subject i; and ε p,ij and ε a,ij are the proportional and additive random residual error terms, respectively, associated with j th concentration for subject i.
| Covariate analysis
Intrinsic and extrinsic covariates influencing eptinezumab clearance (CL) and volume of distribution (V D ) were explored using the stepwise forward addition procedure (α = .05) and backward elimination process (α = .01), with a priori statistical significance criteria for the forward and backward search directions. The potential impacts upon eptinezumab exposure by covariate effects in the final model were characterized using a forest plot to facilitate optimal understanding of covariate effects (as per FDA requirements). 15 The following intrinsic and extrinsic covariates 
Model evaluaƟon/validaƟon
Goodness-of-fit plots, VPC CorrelaƟon plots between PK parameters (EtaCL, EtaV) and covariates (conƟnuous and categorical)
Structural PK model development
EvaluaƟon of the 2-compartment model and the Omega matrix
Final populaƟon PK model
Covariate analysis
Graphical exploraƟon of sources of variability CorrelaƟon plots between PK parameters (EtaCL, EtaV) and covariates (conƟnuous and categorical)
| Model validation/qualification
Model validation/qualification was performed according to FDA and EMA guidance for industry. 6, 16 The quality-of-fit was evaluated using a standard model discrimination process including statistical 
| Dose-and exposure-response modeling
Dose-response relationships were explored prior to performing exposure-response analysis. The primary dose-response analysis was for the change in monthly migraine days (MMD) over weeks 1-12.
PK parameters from the final population PK model were used to derive exposure metrics: area under the curve from time 0 to 12 weeks (AUC 0-12wk ), maximum concentration (C max ), average concentration (C avg ), and trough concentration (C trough ). The exposure-response relationship of plasma eptinezumab was evaluated using these singledose exposure parameters and the change in frequency of MMD (weeks 1-12) from studies CLIN-005, CLIN-006, and CLIN-011. [11] [12] [13] A saturable inhibitory maximum-effect (E max ) model was used to assess relationships between the exposure metrics of eptinezumab and the reduction in MMD. An example for AUC 0-12wk is as follows:
is the predicted effect when AUC = 0 (ie, placebo effect), I max is the maximum inhibitory effect, and AUC 50 is the AUC achieving the half-maximal change in effect and AUC is the area under the concentration-time curve for eptinezumab.
A placebo-anchored approach was used because this method was shown to be more statistically powerful than a simple placebo-corrected analysis for use in dose-response analyses. 18 Key secondary efficacy endpoints were also assessed in the exposure-response analysis. These endpoints included ≥75% migraine responder rates (weeks 1-4), ≥75% migraine responder rate (weeks 1-12), and ≥50% migraine responder rates (weeks 1-12). A logistic regression analysis was performed to explore associations between eptinezumab exposures (ie, AUC 0-12wk, C avg , C trough , C max ) and these categorical endpoints.
| RE SULTS
| Patients/subjects
A total of 2123 patients and subjects from eight clinical studies who received eptinezumab were included in the population PK analysis. The number of patients/subjects receiving each dose of eptinezumab included in the PK and exposure-response populations from each study is summarized in 
| Population pharmacokinetics
The concentration-time profile of eptinezumab following IV dos- A stepwise covariate analysis was performed to identify sources of variability in PK parameters of eptinezumab. Consistent with the pharmacokinetics that are typical for monoclonal antibodies (mAbs), 19 CL and the central volume of distribution (Vc) of eptinezumab were 0.00620 L h −1 (0.15 L day −1 ) and 3.64 L, respectively.
The C max for eptinezumab was 37.3 μg mL −1 following a single IV administration of 100 mg and 114 μg mL −1 after a single dose of 300 mg.
The median time to C max (T max ) was 30 minutes for a 30-minute IV administration and 60 minutes for a 60-minute IV administration (ie, immediately after the completion of the IV delivery 
| Dose-and exposure-response analyses
The eptinezumab dose-response relationship for change in the frequency of MMD (primary endpoint) over weeks 1-12 is illustrated in Figure 6 . As seen in the figure, the treatment benefit is Figure 3B ). Doses of 100 mg or greater were generally associated with greater reductions in migraine days from baseline for both EM and CM. Figure 6 illustrates the exposure-response relationship for AUC 0-12wk . An AUC 0-12wk of 15 000 h·μg mL −1 or higher tended to produce a sustained decrease in migraine days compared with baseline. This exposure corresponds to the average AUC 0-12wk after administration of a 100-mg IV dose of eptinezumab. Similar decreases in the number of migraine days were observed for increasing C max , C avg , and C trough (data not shown). Changes in AUC 0−τ relative to reference Overall, there was a statistically significant effect of eptinezumab exposure and these endpoints (P < .05 for all three comparisons).
In particular, the third quartile of AUC 0-12wk (corresponding to an ~100-mg dose of eptinezumab) appeared to show a higher probability of response for all secondary endpoints, compared to the first and second quartiles of AUC 0-12wk (corresponding to ~10 and 30-mg doses of eptinezumab, respectively). There was a plateau of effect for exposures associated with doses >100 mg.
| D ISCUSS I ON
Monoclonal antibodies targeted against the CGRP ligand or receptor represent a mechanism-based approach to therapy that specifically ics and in binding characteristics that have the potential to influence efficacy and tolerability. [21] [22] [23] [24] These pharmacologic differences likely explain the dosing regimens of the available agents. Some agents require a loading dose (ie, galcanezumab) and some are administered monthly (ie, galcanezumab, erenumab) rather than every 12 weeks. [25] [26] [27] [28] [29] Fremanezumab can be administered either monthly or quarterly, with the quarterly dosing requiring three separate injections. 30 Eptinezumab was designed to provide rapid and sustained efficacy due to the targeting of the soluble CGRP ligand with high selectivity and affinity paired with a IV route of administration every 12 weeks. 14 22 which are administered subcutaneously.
Delivery by the subcutaneous route of administration requires time for absorption, a process that is also associated with a loss of active drug or reduced bioavailability. 32 Due to these issues, subcutaneous administration can lead to the need to administer higher doses, more frequent administration, or a combination of both in order to achieve and maintain therapeutic exposure.
The exposure-response analysis demonstrated a trend toward increased efficacy with increased exposure. Exposure following the administration of eptinezumab 30 mg or less was insufficient to meet the EC 90 estimates for change in the frequency of MMD.
Furthermore, although the number of patients evaluated that received 30 mg was lower (n = 330) than the number receiving 100 mg (n = 691) or 300 mg (n = 687), measures of efficacy from the model (EC 50 for AUC 0-12wk exposures) suggested that doses greater than 30 mg would be required to achieve a plateau for statistically reducing the number of migraine days over weeks 1-12. As eptinezumab doses increased to 100 mg, there was an increased probability of a reduction in the frequency of MMD over weeks 1-12, with a plateau of effect as the dose was further increased to 300 mg. This similar efficacy between the 100-mg and 300-mg doses supports the notion of a lowest effective dose of 100 mg.
In general, an AUC 0-12wk of 15 000 h·μg mL −1 or higher tended to produce a sustained decrease in migraine days compared to baseline. Notably, this level is below the average AUC 0-12wk produced by a single 100-mg dose (ie, 17 900 h·μg mL −1 A similar exposure-response analysis conducted with the anti-CGRP mAb galcanezumab that used a lower threshold for efficacy (EC 50 ) revealed that the EC 50 related to the rate of dissipation of migraine headache days per month was achieved only at some dose levels and only for a portion of the dosing interval. 33 In data from the FDA drug-approval package, the population PK estimated EC 50 for galcanezumab was 43.9 μg mL −1 , a level that is achieved only via 240-mg monthly dosing and only for approximately half of the dosing interval (as measured by the median concentration). 33 This finding may have clinical relevance because it suggests that patients may not be achieving drug concentrations adequate to prevent migraines for significant portions of the dosing interval. Exposure-response information for erenumab provided in the FDA drug-approval package indicated that an estimated plasma concentration of 5.1 μg mL was required to achieve the EC 50 for reduction in the probability of MMD in EM patients. 34 No patients receiving a 70-mg dose of erenumab reached EC 50 exposure levels on the first day of dosing, and 64%
achieved EC 50 exposure levels within the first week of administration. 34 For fremanezumab, the maximal fractional reduction in MMD was described by an E max function with only plasma concentration over the dosing interval, C avg , provided as an exposure metric. The average concentration required to achieve the EC 50 was estimated to be 3.6 μg mL −1 . 35 The less than optimal exposure-response results associated with these anti-CGRP agents may be at least partially explained by the PK profiles associated with their subcutaneous administration, which results in a longer time to T max and incomplete bioavailability. This contrasts with the high binding affinity and IV administration of eptinezumab, which has 100% bioavailability and a T max at the end of the IV administration, resulting in faster and robust achievement of therapeutically effective concentrations.
| CON CLUS IONS
This population PK and exposure-response analysis demonstrates that eptinezumab exhibits linear pharmacokinetics, with C max achieved at the end of the IV administration (T max ). The relatively low exposure metrics required to achieve EC 90 and half-life of 27 days support less frequent, every 12 weeks, IV administration with 100 mg or greater. The relatively small change in clearance associated with patient-related factors (eg, body weight), the absence of dose-limiting toxicity, and the relatively flat exposure response at doses of 100-300 mg support that there is no need for dose adjustments for patient-related factors. There was increased efficacy for both the primary and secondary endpoints with increased exposure of eptinezumab followed by a plateau of effect. The 100-mg and 300-mg doses provide exposures that exceed the EC 90 estimates for AUC 0-12wk , C max , C avg , and C trough in both EM and CM patients.
These data demonstrate that eptinezumab 100 mg, administered every 12 weeks, is an appropriate dosing regimen for patients with episodic or chronic migraine.
